{"id":42431,"date":"2023-11-20T02:30:04","date_gmt":"2023-11-20T08:30:04","guid":{"rendered":"https:\/\/stage.cancerimagingarchive.net\/tcia-citation\/her2-tumor-rois-pub\/"},"modified":"2023-11-20T02:30:04","modified_gmt":"2023-11-20T08:30:04","slug":"her2-tumor-rois-pub","status":"publish","type":"tcia_citation","link":"https:\/\/stage.cancerimagingarchive.net\/tcia-citation\/her2-tumor-rois-pub\/","title":{"rendered":"HER2-TUMOR-ROIS-PUB"},"template":"","class_list":["post-42431","tcia_citation","type-tcia_citation","status-publish"],"tcia_citation_type":"Publication Citation","tcia_citation_text":"<p>Farahmand, S., Fernandez, A. I., Ahmed, F. S., Rimm, D. L., Chuang, J. H., Reisenbichler, E., &amp; Zarringhalam, K. (2022). <strong>Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer.<\/strong> In Modern Pathology (Vol. 35, Issue 1, pp. 44\u201351). Elsevier BV.\u00a0<a href=\"https:\/\/doi.org\/10.1038\/s41379-021-00911-w\">https:\/\/doi.org\/10.1038\/s41379-021-00911-w<\/a><\/p>\n","tcia_citation_statement":"","tcia_citation_doi":"10.1038\/s41379-021-00911-w","_links":{"self":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/v1\/citations\/42431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/v1\/citations"}],"about":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/wp\/v2\/types\/tcia_citation"}],"wp:attachment":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/wp\/v2\/media?parent=42431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}